Topical and systemic formulation options for cutaneous T cell lymphomas

Research output: Contribution to journalReview articlepeer-review

Abstract

Although various anti-cutaneous T-cell lymphoma (CTCL) therapies are available for clinical use, appropriate chemotherapy lines for the treatment of CTCLs have yet to be established. Therefore, to date, various clinical trials for the treatment of advanced CTCLs are ongoing. In this review, we evaluate the therapeutic options that are available in clinical practice for treatment of early-and advanced-stage CTCLs (targeted therapies, histone deacetylase (HDAC) inhibitors, retinoids, interferons, cytotoxic drugs, etc.). We also examine clinical trials of novel regimens for the treatment of CTCLs.

Original languageEnglish
Article number200
Pages (from-to)1-14
Number of pages14
JournalPharmaceutics
Volume13
Issue number2
DOIs
Publication statusPublished - 2021 Feb
Externally publishedYes

Keywords

  • Bexarotene
  • CTCL
  • HDAC inhibitors
  • Interferon
  • Targeted therapy
  • Topical formulation

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Topical and systemic formulation options for cutaneous T cell lymphomas'. Together they form a unique fingerprint.

Cite this